Skeletal muscle glucose uptake in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy

Skeletal muscle glucose uptake in patients with chronic myeloid leukemia on tyrosine kinase inhibitor therapy - Tyrosine kinase inhibitors and glucose uptake

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON48288

Enrollment

Registered

2019-10-21

Start date

2020-02-20

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

blood cancer chronic myeloid leukemia

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age: *18 years - Fasting glucose level: * 6,0 mmol/l - CML patients: o Nilotinib treatment for at least 6 months prior to study inclusion OR o Imatinib treatment for at least 6 months prior to study inclusion

Exclusion criteria

Exclusion criteria: - Contra-indication to exercise testing according to the ACC/AHA guidelines - Incapable to provide informed consent - Subgroup op patients undergoing [18F]FDG PET/CT scanning: o Renal dysfunction with MDRD

Design outcomes

Primary

Measure	Time frame
Differences in area under the glucose disappearance curve upon a single glucose bolus after an exercise bout. Standard uptake value (SUV) of [18F]FDG as determined on PET/CT images.	—

Secondary

Measure	Time frame
-	—

Countries

Netherlands

Outcome results